
---
title: 'MIT_ 一种对抗肿瘤的秘密方法'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/21/205534pvcv2cr24t2p4rlg.jpg'
author: 科学网
comments: false
date: Sun, 21 Nov 2021 20:52:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/21/205534pvcv2cr24t2p4rlg.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: "arial black", "avant garde";">MIT</span><span style="font-family: 黑体, SimHei; font-size: 24px;">: 一种对抗肿瘤的秘密方法</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><span style="color: #333333; background-color: #FFFFFF; font-size: 18px; font-family: "arial black", "avant garde";">Graphical abstract</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/21/205534pvcv2cr24t2p4rlg.jpg" title alt="1-s2.0-S1074761321004581-fx1_lrg.jpg" referrerpolicy="no-referrer"></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202111/21/211142d164g5cjsj3jml3w.jpg" title alt="360截图20211121210912359.jpg" referrerpolicy="no-referrer"><br></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" target="_blank" style="font-size: 18px; font-family: "times new roman";">MIT researchers have identified a specialized subset of dendritic cells that help stimulate T cells to attack tumors. In this image, the blue represents a protein found on dendritic cell surfaces, and the purple stain reveals tumor proteins that the dendritic cell uses to “disguise” itself as a tumor cell. Cell nuclei are labeled in yellow. Credit: Ellen Duong and Tim Fessenden</a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国麻省理工学院（</span><a href="http://web.mit.edu/" target="_blank" style="font-size: 18px; font-family: "times new roman";">Massachusetts Institute of Technology</a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-family: 宋体;">简称</span>MIT<span style="font-family: 宋体;">）</span>2021<span style="font-family: 宋体;">年</span>11<span style="font-family: 宋体;">月</span>19<span style="font-family: 宋体;">日提供的消息，麻省理工学院科赫综合癌症研究所</span>(Koch Institute for Integrative Cancer Research at MIT)<span style="font-family: 宋体;">、麻省理工学院生物系（</span>Department of Biology, MIT<span style="font-family: 宋体;">）、麻省理工学院生物工程系（</span>Department of Biological Engineering, MIT,<span style="font-family: 宋体;">）以及麻省理工学院和哈佛大学的</span>MGH<span style="font-family: 宋体;">拉根研究所</span>(Ragon Institute of MGH, MIT and Harvard)<span style="font-family: 宋体;">的研究人员合作发现了一种对抗肿瘤的秘密方法（</span></span><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" target="_blank" style="font-size: 18px; font-family: "times new roman";">A stealthy way to combat tumors</a><span style="font-size: 18px; font-family: "times new roman";">）</span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在适当的情况下，人体的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞可以检测并摧毁癌细胞。然而，在大多数癌症患者中，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞一旦进入肿瘤周围的环境就会被解除武装。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">科学家们正试图找到帮助治疗癌症病人的方法，让那些缺乏活力的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞起死回生。这一领域的很多研究，即癌症免疫疗法，都集中于寻找直接刺激这些</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的方法。麻省理工学院的研究人员现在发现了一种可能的新方法，通过招募一群被称为树突细胞（</span></span><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">dendritic cells</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）的辅助免疫细胞来间接激活这些</span>T<span style="font-size: 18px; font-family: 宋体;">细胞。相关研究结果于</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>11<span style="font-size: 18px; font-family: 宋体;">月</span>19<span style="font-size: 18px; font-family: 宋体;">日已经在《免疫》（</span></span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Immunity</span></a><span style="font-size: 18px; font-family: "times new roman";">）杂志网站发表——</span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Ellen Duong,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Tim B. Fessenden,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Emi Lutz,</span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Teresa Dinter</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Leon Yim,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Sarah Blatt,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Arjun Bhutkar</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Karl Dane Wittrup,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1074761321004581?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Stefani Spranger.</span></a><span style="font-size: 18px; font-family: "times new roman";"> Type-I interferon activates MHC-I-dressed CD11b<sup>+</sup> conventional dendritic cells to promote protective anti-tumor CD8<sup>+</sup> T cell immunity. </span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Immunity</span></a><span style="font-size: 18px; font-family: "times new roman";">, Available online 19 November 2021. </span><a href="http://dx.doi.org/10.1016/j.immuni.2021.10.020" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1016/j.immuni.2021.10.020</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在一项新的研究中，研究人员确定了树突状细胞的一个特定子集，它们具有激活</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的独特方式。这些树突细胞可以将自身包裹在肿瘤蛋白（</span></span><a href="https://medicalxpress.com/tags/tumor+proteins/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">tumor proteins</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）中，从而模仿癌细胞并触发强烈的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞反应。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">MIT<span style="font-size: 18px; font-family: 宋体;">霍华德</span>S.<span style="font-size: 18px; font-family: 宋体;">和琳达·斯特恩的职业发展教授</span>(Howard S. and Linda B. Stern Career Development Professor at MIT)<span style="font-size: 18px; font-family: 宋体;">、</span>MIT<span style="font-size: 18px; font-family: 宋体;">的科赫综合癌症研究（</span>MIT's Koch Institute for Integrative Cancer Research<span style="font-size: 18px; font-family: 宋体;">）成员史蒂芬妮·施普兰格尔（</span>Stefani Spranger<span style="font-size: 18px; font-family: 宋体;">）说：“我们知道对于抗肿瘤免疫反应（</span>antitumor </span><a href="https://medicalxpress.com/tags/immune+response/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">immune response</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）而言，树突细胞是非常重要的</span>,<span style="font-size: 18px; font-family: 宋体;">但我们并不知道真正构成最优树突细胞响应肿瘤的究竟是什么。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">她说，研究结果表明，寻找刺激树突状细胞的方法可以帮助提高癌症免疫治疗的有效性。在一项对老鼠的研究中，研究人员发现，刺激这些树突细胞可以减缓黑素瘤和结肠肿瘤的生长。史蒂芬妮·施普兰格尔是上述论文的通讯作者，而论文的第一作者是麻省理工学院研究生</span>Ellen Duong<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">自发消退（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" target="_blank">Spontaneous regression</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当肿瘤开始形成时，它们会产生</span>T<span style="font-size: 18px; font-family: 宋体;">细胞识别为外来的癌蛋白。这有时允许</span>T<span style="font-size: 18px; font-family: 宋体;">细胞在肿瘤变大之前将其消灭。在其他情况下，肿瘤能够分泌化学信号，使</span>T<span style="font-size: 18px; font-family: 宋体;">细胞失去活性，允许肿瘤继续不受控制地生长。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">树突细胞可以帮助激活抗肿瘤</span>T<span style="font-size: 18px; font-family: 宋体;">细胞，但树突细胞有许多不同的亚型，它们在</span>T<span style="font-size: 18px; font-family: 宋体;">细胞激活中的作用还尚未完全明确。在这项研究中，麻省理工学院的团队想要研究哪些类型的树突细胞参与了</span>T<span style="font-size: 18px; font-family: 宋体;">细胞反应，从而成功地消除了肿瘤。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">为了做到这一点，他们从一种肌肉肿瘤中发现了一种肿瘤细胞系，这种细胞系已经在老鼠体内自发退化。史蒂芬妮·施普兰格尔说，这样的细胞系很难找到，因为如果它们不能形成肿瘤，研究人员通常不会将它们保存在周围。</span><span style="font-family: "times new roman"; font-size: 18px;"> </span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在研究小鼠时，他们将退化细胞系产生的肿瘤与一种结肠癌进行了比较，后者形成的肿瘤在植入体内后会变得更大。研究人员发现，在进展中的肿瘤中，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的反应很快就消耗殆尽了，而在消退的肿瘤中，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞仍然有功能。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">然后，研究人员分析了这些肿瘤中的树突细胞群。树突细胞的主要功能之一是从死亡细胞</span>(<span style="font-size: 18px; font-family: 宋体;">如癌细胞或受病原体感染的细胞</span>)<span style="font-size: 18px; font-family: 宋体;">中获取碎片，然后将蛋白质片段呈现给</span>T<span style="font-size: 18px; font-family: 宋体;">细胞，提醒它们感染或肿瘤。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">抗肿瘤免疫所需的最著名的树突细胞类型是</span>DC1<span style="font-size: 18px; font-family: 宋体;">细胞（</span>DC1 cells<span style="font-size: 18px; font-family: 宋体;">），它与能够消除癌细胞的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞相互作用。然而，研究人员发现，肿瘤消退并不需要</span>DC1<span style="font-size: 18px; font-family: 宋体;">细胞。相反，利用单细胞</span>RNA<span style="font-size: 18px; font-family: 宋体;">测序技术，他们发现了</span>DC2<span style="font-size: 18px; font-family: 宋体;">细胞的一种之前未知的激活状态，</span>DC2<span style="font-size: 18px; font-family: 宋体;">细胞是一种不同类型的树突细胞，在消退的肿瘤中驱动</span>T<span style="font-size: 18px; font-family: 宋体;">细胞激活。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">麻省理工学院的研究小组发现，这些树突细胞不是吞食细胞碎片，而是从肿瘤细胞上刮下称为</span>MHC<span style="font-size: 18px; font-family: 宋体;">复合体（</span>MHC complexes<span style="font-size: 18px; font-family: 宋体;">）的蛋白质，并将它们展示在自身的表面上。当</span>T<span style="font-size: 18px; font-family: 宋体;">细胞遇到这些伪装成肿瘤细胞的树突细胞时，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞就会被强烈激活并开始杀死肿瘤细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">这一特殊的树突细胞群似乎是被一类干扰素（</span>interferon<span style="font-size: 18px; font-family: 宋体;">）激活的，一类干扰素是细胞在应对病毒感染时通常产生的信号分子。研究人员在结肠和黑色素瘤肿瘤中发现了一小群这种树突细胞，但它们没有被适当地激活。然而，如果他们用干扰素治疗这些肿瘤，树突细胞（</span></span><a href="https://medicalxpress.com/tags/dendritic+cells/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">dendritic cells</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）开始刺激</span>T<span style="font-size: 18px; font-family: 宋体;">细胞攻击肿瘤细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">靶向治疗（</span></strong><strong><span style="font-size: 18px; font-family: 宋体;"></span></strong><strong><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" target="_blank">Targeted therapy</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">一些类型的干扰素已经被用来帮助治疗癌症，但是如果全身使用的话，它会产生广泛的副作用。史蒂芬妮·施普兰格尔说，这项研究的发现表明，以一种非常有针对性的方式将干扰素传递给肿瘤细胞，或者使用一种能刺激肿瘤细胞产生</span>I<span style="font-size: 18px; font-family: 宋体;">型干扰素（</span>type I interferon<span style="font-size: 18px; font-family: 宋体;">）的药物，可能是有益的。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">研究人员现在计划调查需要多少</span>I<span style="font-size: 18px; font-family: 宋体;">型干扰素才能产生强烈的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞反应。大多数肿瘤细胞产生少量的</span>I<span style="font-size: 18px; font-family: 宋体;">型干扰素，但不足以激活激活</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的树突细胞群。另一方面，过多的干扰素对细胞是有毒的。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">史蒂芬妮·施普兰格尔说：“我们的免疫系统天生就会对</span>I<span style="font-size: 18px; font-family: 宋体;">型干扰素的细微差别做出非常显著的反应，从免疫学的角度来看，这是一件有趣的事情。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://medicalxpress.com/news/2021-11-stealthy-combat-tumors.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-10-avenues-optimisation-dendritic-cell-based-cancer.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">New avenues for the optimisation of dendritic cell-based cancer immunotherapies</span></a></p><p style="line-height: 2em;"><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;" target="_blank"><span style="font-family: "arial black", "avant garde";">Highlights</span></a><br></p><p style="margin-right: 1px; background: whitesmoke; line-height: 2em;"><span style="color: #2E2E2E; font-size: 18px; font-family: "times new roman";">• IFN-I induces a stimulatory DC2 state (ISG<sup>+</sup> DCs) that activates CD8<sup>+</sup>T cells</span></p><p style="margin-right: 1px; background: whitesmoke; line-height: 2em;"><span style="color: #2E2E2E; font-size: 18px; font-family: "times new roman";">• <em>B2M</em><sup>−/−</sup> ISG<sup>+</sup> DCs acquire and present tumor-derived pMHC class I complexes</span></p><p style="margin-right: 1px; background: whitesmoke; line-height: 2em;"><span style="color: #2E2E2E; font-size: 18px; font-family: "times new roman";">• Precluding MHC class I transfer to ISG<sup>+</sup> DCs ablates T cell responses in <em>Batf3</em><sup>−/−</sup> mice</span></p><p style="margin-right: 1px; background: whitesmoke; line-height: 2em;"><span style="color: #2E2E2E; font-size: 18px; font-family: "times new roman";">• ISG<sup>+</sup> DCs can be induced by exogenous IFN-β addition to drive anti-tumor immunity</span></p><p style="line-height: 2em;"><a href="https://www.cell.com/immunity/fulltext/S1074-7613(21)00458-1" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Summary</span></a></p><p style="line-height: 2em;"><span style="color: #2E2E2E; font-size: 18px; font-family: "times new roman";">Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor immunity. To delineate the DC states associated with productive anti-tumor T cell immunity, we compared spontaneously regressing and progressing tumors. Tumor-reactive CD8<sup>+</sup> T cell responses in <em>Batf3<sup>−/−</sup></em> mice lacking type 1 DCs (DC1s) were lost in progressor tumors but preserved in regressor tumors. Transcriptional profiling of intra-tumoral DCs within regressor tumors revealed an activation state of CD11b<sup>+</sup> conventional DCs (DC2s) characterized by expression of <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/interferon" title="Learn more about interferon from ScienceDirect's AI-generated Topic Pages" target="_blank">interferon</a> (IFN)-stimulated genes (ISGs) (ISG<sup>+</sup>DCs). ISG<sup>+</sup> DC-activated CD8<sup>+</sup> T cells <em>ex vivo</em> comparably to DC1. Unlike cross-presenting DC1, ISG<sup>+</sup> DCs acquired and presented intact tumor-derived peptide-major histocompatibility complex class I (MHC class I) complexes. Constitutive type I <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/interferon-production" title="Learn more about IFN production from ScienceDirect's AI-generated Topic Pages" target="_blank">IFN production</a> by regressor tumors drove the ISG<sup>+</sup> DC state, and activation of MHC class I-dressed ISG<sup>+</sup> DCs by exogenous IFN-β rescued anti-tumor immunity against progressor tumors in <em>Batf3<sup>−/−</sup></em> mice. The ISG<sup>+</sup> DC gene signature is detectable in human tumors. Engaging this functional DC state may present an approach for the treatment of human disease.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1313383.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1313383.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1313153.html" target="_black">细菌可能是可持续提取稀土元素技术的关键</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-212210-1313389.html" target="_black">《智能与模糊系统杂志》上发表的近50篇文章被撤销</a>                    <!--大赛结束-->
                                        
  
</div>
            